<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35040152</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1600-065X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>307</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunological reviews</Title>
          <ISOAbbreviation>Immunol Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Regulatory strategies limiting endosomal Toll-like receptor activation in B cells.</ArticleTitle>
        <Pagination>
          <StartPage>66</StartPage>
          <EndPage>78</EndPage>
          <MedlinePgn>66-78</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/imr.13065</ELocationID>
        <Abstract>
          <AbstractText>The recognition of pathogen-associated nucleic acid (NA) promotes effective immunity against invading pathogens. However, endosomal Toll-like receptor (TLR) activation by self-NA also underlies the pathogenesis of systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). For this reason, the activation thresholds of NA-sensing TLRs must be tightly regulated to balance protective and pathogenic immune responses. In this study, we will provide an overview of the evolutionary mechanisms designed to limit the aberrant activation of endosomal TLRs by self-ligands, focusing on four broad strategies. These include the following: 1) the production of nucleases able to degrade self-DNA and RNA; 2) the cell-specific regulation of endosomal TLR expression; 3) the spatial and temporal control of TLR positioning at a sub-cellular level; and 4) the modulation of downstream TLR signaling cascades. Given the critical role of B cells in lupus pathogenesis, where possible, we will describe evidence for B cell-specific induction of these regulatory mechanisms. We will also highlight our own work showing how modulation of B cell endolysosomal flux tunes NA-sensing TLR activation signals. In the face of inevitable generation of self-NA during normal cellular turnover, these parallel mechanisms are vital to protect against pathogenic inflammation.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Acharya</LastName>
            <ForeName>Mridu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Seattle Children's Research Institute, Seattle, Washington, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jackson</LastName>
            <ForeName>Shaun W</ForeName>
            <Initials>SW</Initials>
            <Identifier Source="ORCID">0000-0002-7024-5252</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Seattle Children's Research Institute, Seattle, Washington, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01AR073938</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01AR075813</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AR073938</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI151167</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AR075813</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R03 AI139716</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Immunol Rev</MedlineTA>
        <NlmUniqueID>7702118</NlmUniqueID>
        <ISSNLinking>0105-2896</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051217">Toll-Like Receptor 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051199" MajorTopicYN="N">Toll-Like Receptor 7</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051217" MajorTopicYN="N">Toll-Like Receptor 9</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051193" MajorTopicYN="Y">Toll-Like Receptors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">B cells</Keyword>
        <Keyword MajorTopicYN="N">Toll-like receptors</Keyword>
        <Keyword MajorTopicYN="N">endolysosomal trafficking</Keyword>
        <Keyword MajorTopicYN="N">non-canonical autophagy</Keyword>
        <Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35040152</ArticleId>
        <ArticleId IdType="mid">NIHMS1770718</ArticleId>
        <ArticleId IdType="pmc">PMC8986562</ArticleId>
        <ArticleId IdType="doi">10.1111/imr.13065</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>World Health Organization
Weekly epidemiological update on COVID-19 – 2 November 2021. In. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---2-november-2021.</Citation>
        </Reference>
        <Reference>
          <Citation>The pandemic’s true death toll. In. The Economist
2021. https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates.</Citation>
        </Reference>
        <Reference>
          <Citation>Hou B, Saudan P, Ott G, et al.
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity. 2011;34(3):375–384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3064721</ArticleId>
            <ArticleId IdType="pubmed">21353603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holborow EJ, Weir DM, Johnson GD. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br Med J. 1957;2(5047):732–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1962253</ArticleId>
            <ArticleId IdType="pubmed">13460368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416(6881):603–607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11948342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shlomchik MJ. Activating systemic autoimmunity: B’s, T’s, and tolls. Current opinion in immunology. 2009;21(6):626–633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2787881</ArticleId>
            <ArticleId IdType="pubmed">19800208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arbuckle MR, McClain MT, Rubertone MV, et al.
Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–1533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregersen PK, Behrens TW. Genetics of autoimmune diseases--disorders of immune homeostasis. Nat Rev Genet. 2006;7(12):917–928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17139323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, et al.
WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med. 2011;208(10):2033–2042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3182055</ArticleId>
            <ArticleId IdType="pubmed">21875954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groom JR, Fletcher CA, Walters SN, et al.
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. The Journal of experimental medicine. 2007;204(8):1959–1971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118661</ArticleId>
            <ArticleId IdType="pubmed">17664289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teichmann LL, Schenten D, Medzhitov R, Kashgarian M, Shlomchik MJ. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity. 2013;38(3):528–540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3638041</ArticleId>
            <ArticleId IdType="pubmed">23499488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua Z, Gross AJ, Lamagna C, et al.
Requirement for MyD88 Signaling in B Cells and Dendritic Cells for Germinal Center Anti-Nuclear Antibody Production in Lyn-Deficient Mice. J Immunol. 2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4101002</ArticleId>
            <ArticleId IdType="pubmed">24379120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu R, Munroe ME, Guthridge JM, et al.
Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun. 2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5079766</ArticleId>
            <ArticleId IdType="pubmed">27338520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munroe ME, Lu R, Zhao YD, et al.
Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014–2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4959992</ArticleId>
            <ArticleId IdType="pubmed">27088255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey’s end?
Rheumatology (Oxford). 2007;46(7):1052–1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17500073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis and rheumatism. 1990;33(5):634–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2346519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW. Altered B cell signalling in autoimmunity. Nat Rev Immunol. 2017;17(7):421–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5523822</ArticleId>
            <ArticleId IdType="pubmed">28393923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25(3):417–428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16973389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soni C, Wong EB, Domeier PP, et al.
B cell-intrinsic TLR7 signaling is essential for the development of spontaneous germinal centers. J Immunol. 2014;193(9):4400–4414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4201954</ArticleId>
            <ArticleId IdType="pubmed">25252960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santiago-Raber ML, Dunand-Sauthier I, Wu T, et al.
Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J Autoimmun. 2010;34(4):339–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19944565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fairhurst AM, Hwang SH, Wang A, et al.
Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur J Immunol. 2008;38(7):1971–1978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993003</ArticleId>
            <ArticleId IdType="pubmed">18521959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nickerson KM, Christensen SR, Shupe J, et al.
TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol. 2010;184(4):1840–1848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4098568</ArticleId>
            <ArticleId IdType="pubmed">20089701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson SW, Scharping NE, Kolhatkar NS, et al.
Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol. 2014;192(10):4525–4532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4041708</ArticleId>
            <ArticleId IdType="pubmed">24711620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh ER, Pisitkun P, Voynova E, et al.
Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(40):16276–16281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3479588</ArticleId>
            <ArticleId IdType="pubmed">22988104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang SH, Lee H, Yamamoto M, et al.
B cell TLR7 expression drives anti-RNA autoantibody production and exacerbates disease in systemic lupus erythematosus-prone mice. Journal of immunology. 2012;189(12):5786–5796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3544945</ArticleId>
            <ArticleId IdType="pubmed">23150717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tilstra JS, John S, Gordon RA, et al.
B cell-intrinsic TLR9 expression is protective in murine lupus. J Clin Invest. 2020;130(6):3172–3187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7260024</ArticleId>
            <ArticleId IdType="pubmed">32191633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Mayouf SM, Sunker A, Abdwani R, et al.
Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43(12):1186–1188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22019780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozcakar ZB, Foster J 2nd, Diaz-Horta O, et al.
DNASE1L3 mutations in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 2013;65(8):2183–2189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23666765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zochling J, Newell F, Charlesworth JC, et al.
An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. Arthritis Res Ther. 2014;16(5):438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4230517</ArticleId>
            <ArticleId IdType="pubmed">25332064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acosta-Herrera M, Kerick M, Gonzalez-Serna D, et al.
Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. Ann Rheum Dis. 2019;78(3):311–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6800208</ArticleId>
            <ArticleId IdType="pubmed">30573655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sisirak V, Sally B, D’Agati V, et al.
Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell. 2016;166(1):88–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5030815</ArticleId>
            <ArticleId IdType="pubmed">27293190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisenburger T, von Neubeck B, Schneider A, et al.
Epistatic Interactions Between Mutations of Deoxyribonuclease 1-Like 3 and the Inhibitory Fc Gamma Receptor IIB Result in Very Early and Massive Autoantibodies Against Double-Stranded DNA. Front Immunol. 2018;9:1551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6041390</ArticleId>
            <ArticleId IdType="pubmed">30026744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soni C, Perez OA, Voss WN, et al.
Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA. Immunity. 2020;52(6):1022–1038
 e1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7306002</ArticleId>
            <ArticleId IdType="pubmed">32454024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartl J, Serpas L, Wang Y, et al.
Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. J Exp Med. 2021;218(5).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8020718</ArticleId>
            <ArticleId IdType="pubmed">33783474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet. 2000;25(2):177–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10835632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasutomo K, Horiuchi T, Kagami S, et al.
Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001;28(4):313–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11479590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gavin AL, Huang D, Huber C, et al.
PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. Nat Immunol. 2018;19(9):942–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6105523</ArticleId>
            <ArticleId IdType="pubmed">30111894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A. 2012;109(47):19386–19391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3511090</ArticleId>
            <ArticleId IdType="pubmed">23132945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida H, Okabe Y, Kawane K, Fukuyama H, Nagata S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol. 2005;6(1):49–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15568025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Wiedeman A, Agrawal N, et al.
Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol. 2013;190(6):2536–2543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3594466</ArticleId>
            <ArticleId IdType="pubmed">23382559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata T, Taoka M, Saitoh S-I, et al.
Nucleosides drive histiocytosis in SLC29A3 disorders by activating TLR7. bioRxiv. 2019:2019.2012.2016.877357.</Citation>
        </Reference>
        <Reference>
          <Citation>Morgan NV, Morris MR, Cangul H, et al.
Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 2010;6(2):e1000833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2816679</ArticleId>
            <ArticleId IdType="pubmed">20140240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Priya TP, Philip N, Molho-Pessach V, Busa T, Dalal A, Zlotogorski A. H syndrome: novel and recurrent mutations in SLC29A3. Br J Dermatol. 2010;162(5):1132–1134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20199539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang YF, Wei W, Tangtanatakul P, et al.
Multi-ancestral GWAS identifies shared and Asian-specific loci for SLE and links type III interferon signaling and lysosomal function to the disease. Arthritis Rheumatol. 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34783190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petes C, Odoardi N, Gee K. The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome. Front Immunol. 2017;8:1075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5591332</ArticleId>
            <ArticleId IdType="pubmed">28928743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Lee BL, Deguine J, John S, Shlomchik MJ, Barton GM. Tissue-Resident Macrophages Are Locally Programmed for Silent Clearance of Apoptotic Cells. Immunity. 2017;47(5):913–927
 e916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728676</ArticleId>
            <ArticleId IdType="pubmed">29150239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng Y, Martin DA, Kenkel J, Zhang K, Ogden CA, Elkon KB. Innate and adaptive immune response to apoptotic cells. J Autoimmun. 2007;29(4):303–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2100400</ArticleId>
            <ArticleId IdType="pubmed">17888627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deane JA, Pisitkun P, Barrett RS, et al.
Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity. 2007;27(5):801–810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2706502</ArticleId>
            <ArticleId IdType="pubmed">17997333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312(5780):1669–1672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16709748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian S, Tus K, Li QZ, et al.
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A. 2006;103(26):9970–9975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1502563</ArticleId>
            <ArticleId IdType="pubmed">16777955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K, Kurien BT, Zimmerman SL, et al.
X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjogren’s Syndrome. Arthritis Rheumatol. 2016;68(5):1290–1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5019501</ArticleId>
            <ArticleId IdType="pubmed">26713507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scofield RH, Bruner GR, Namjou B, et al.
Klinefelter’s syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58(8):2511–2517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824898</ArticleId>
            <ArticleId IdType="pubmed">18668569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souyris M, Cenac C, Azar P, et al.
TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3(19).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29374079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouchess ML, Arpaia N, Souza G, et al.
Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation. Immunity. 2011;35(5):721–732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3230302</ArticleId>
            <ArticleId IdType="pubmed">22078797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ewald SE, Lee BL, Lau L, et al.
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature. 2008;456(7222):658–662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2596276</ArticleId>
            <ArticleId IdType="pubmed">18820679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latz E, Schoenemeyer A, Visintin A, et al.
TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5(2):190–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14716310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee BL, Moon JE, Shu JH, et al.
UNC93B1 mediates differential trafficking of endosomal TLRs. Elife. 2013;2:e00291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3576711</ArticleId>
            <ArticleId IdType="pubmed">23426999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casrouge A, Zhang SY, Eidenschenk C, et al.
Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006;314(5797):308–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16973841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kono DH, Haraldsson MK, Lawson BR, et al.
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci U S A. 2009;106(29):12061–12066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2715524</ArticleId>
            <ArticleId IdType="pubmed">19574451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukui R, Saitoh S, Kanno A, et al.
Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity. 2011;35(1):69–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21683627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majer O, Liu B, Woo BJ, Kreuk LSM, Van Dis E, Barton GM. Release from UNC93B1 reinforces the compartmentalized activation of select TLRs. Nature. 2019;575(7782):371–374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6856438</ArticleId>
            <ArticleId IdType="pubmed">31546247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majer O, Liu B, Kreuk LSM, Krogan N, Barton GM. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature. 2019;575(7782):366–370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6856441</ArticleId>
            <ArticleId IdType="pubmed">31546246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honda K, Ohba Y, Yanai H, et al.
Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature. 2005;434(7036):1035–1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15815647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasai M, Linehan MM, Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science. 2010;329(5998):1530–1534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3063333</ArticleId>
            <ArticleId IdType="pubmed">20847273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guiducci C, Ott G, Chan JH, et al.
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. The Journal of experimental medicine. 2006;203(8):1999–2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118381</ArticleId>
            <ArticleId IdType="pubmed">16864658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotoh K, Tanaka Y, Nishikimi A, et al.
Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. The Journal of experimental medicine. 2010;207(4):721–730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2856018</ArticleId>
            <ArticleId IdType="pubmed">20231379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husebye H, Halaas O, Stenmark H, et al.
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J. 2006;25(4):683–692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1383569</ArticleId>
            <ArticleId IdType="pubmed">16467847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol. 2008;9(4):361–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4112825</ArticleId>
            <ArticleId IdType="pubmed">18297073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu Rev Immunol. 2012;30:611–646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22449030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine B, Kroemer G. Biological Functions of Autophagy Genes: A Disease Perspective. Cell. 2019;176(1–2):11–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6347410</ArticleId>
            <ArticleId IdType="pubmed">30633901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henault J, Martinez J, Riggs JM, et al.
Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity. 2012;37(6):986–997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3786711</ArticleId>
            <ArticleId IdType="pubmed">23219390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science. 2007;315(5817):1398–1401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17272685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi K, Taura M, Iwasaki A. The interaction between IKKalpha and LC3 promotes type I interferon production through the TLR9-containing LAPosome. Sci Signal. 2018;11(528).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6462218</ArticleId>
            <ArticleId IdType="pubmed">29717061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez J, Malireddi RK, Lu Q, et al.
Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat Cell Biol. 2015;17(7):893–906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4612372</ArticleId>
            <ArticleId IdType="pubmed">26098576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heckmann BL, Boada-Romero E, Cunha LD, Magne J, Green DR. LC3-Associated Phagocytosis and Inflammation. J Mol Biol. 2017;429(23):3561–3576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5743439</ArticleId>
            <ArticleId IdType="pubmed">28847720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101(4):890–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC508637</ArticleId>
            <ArticleId IdType="pubmed">9466984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Elkon KB, Ma X. Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity. 2004;21(5):643–653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15539151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez J, Cunha LD, Park S, et al.
Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature. 2016;533(7601):115–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4860026</ArticleId>
            <ArticleId IdType="pubmed">27096368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharya M, Sokolovska A, Tam JM, et al.
alphav Integrins combine with LC3 and atg5 to regulate Toll-like receptor signalling in B cells. Nat Commun. 2016;7:10917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4792966</ArticleId>
            <ArticleId IdType="pubmed">26965188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raso F, Sagadiev S, Du S, et al.
alphav Integrins regulate germinal center B cell responses through noncanonical autophagy. J Clin Invest. 2018;128(9):4163–4178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6118577</ArticleId>
            <ArticleId IdType="pubmed">29999501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity. 2008;28(6):799–809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2601674</ArticleId>
            <ArticleId IdType="pubmed">18513998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Martin N, Maldonado P, Gasparrini F, et al.
A switch from canonical to noncanonical autophagy shapes B cell responses. Science. 2017;355(6325):641–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5805088</ArticleId>
            <ArticleId IdType="pubmed">28183981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conway KL, Kuballa P, Khor B, et al.
ATG5 regulates plasma cell differentiation. Autophagy. 2013;9(4):528–537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3627668</ArticleId>
            <ArticleId IdType="pubmed">23327930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pengo N, Scolari M, Oliva L, et al.
Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol. 2013;14(3):298–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23354484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharya M, Raso F, Sagadiev S, et al.
B Cell alphav Integrins Regulate TLR-Driven Autoimmunity. J Immunol. 2020;205(7):1810–1818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7504890</ArticleId>
            <ArticleId IdType="pubmed">32859730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munz C
Autophagy proteins in antigen processing for presentation on MHC molecules. Immunol Rev. 2016;272(1):17–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27319339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantegazza AR, Guttentag SH, El-Benna J, et al.
Adaptor protein-3 in dendritic cells facilitates phagosomal toll-like receptor signaling and antigen presentation to CD4(+) T cells. Immunity. 2012;36(5):782–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3361531</ArticleId>
            <ArticleId IdType="pubmed">22560444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salloum R, Franek BS, Kariuki SN, et al.
Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010;62(2):553–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2832192</ArticleId>
            <ArticleId IdType="pubmed">20112359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigurdsson S, Nordmark G, Goring HH, et al.
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005;76(3):528–537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1196404</ArticleId>
            <ArticleId IdType="pubmed">15657875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Molineros JE, Looger LL, et al.
High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nat Genet. 2016;48(3):323–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4767573</ArticleId>
            <ArticleId IdType="pubmed">26808113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Ma J, Deng Y, et al.
A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. Nat Genet. 2017;49(3):433–437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5400098</ArticleId>
            <ArticleId IdType="pubmed">28135245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou XJ, Lu XL, Lv JC, et al.
Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann Rheum Dis. 2011;70(7):1330–1337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21622776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu B, Chen Y, Wu Q, et al.
The association between single-nucleotide polymorphisms of NCF2 and systemic lupus erythematosus in Chinese mainland population. Clin Rheumatol. 2011;30(4):521–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20842512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alarcon-Riquelme ME, Ziegler JT, Molineros J, et al.
Genome-Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. Arthritis Rheumatol. 2016;68(4):932–943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4829354</ArticleId>
            <ArticleId IdType="pubmed">26606652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim-Howard X, Sun C, Molineros JE, et al.
Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Hum Mol Genet. 2014;23(6):1656–1668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3929085</ArticleId>
            <ArticleId IdType="pubmed">24163247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob CO, Eisenstein M, Dinauer MC, et al.
Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc Natl Acad Sci U S A. 2012;109(2):E59–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258621</ArticleId>
            <ArticleId IdType="pubmed">22203994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson LM, Johansson AC, Gullstrand B, et al.
A single nucleotide polymorphism in the NCF1 gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. Ann Rheum Dis. 2017;76(9):1607–1613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28606963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol. 2007;148(1):79–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868856</ArticleId>
            <ArticleId IdType="pubmed">17286762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Canadien V, Lam GY, et al.
Activation of antibacterial autophagy by NADPH oxidases. Proc Natl Acad Sci U S A. 2009;106(15):6226–6231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2664152</ArticleId>
            <ArticleId IdType="pubmed">19339495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell AM, Kashgarian M, Shlomchik MJ. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Transl Med. 2012;4(157):157ra141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3704198</ArticleId>
            <ArticleId IdType="pubmed">23100627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob CO, Yu N, Yoo DG, et al.
Haploinsufficiency of NADPH Oxidase Subunit Neutrophil Cytosolic Factor 2 Is Sufficient to Accelerate Full-Blown Lupus in NZM 2328 Mice. Arthritis Rheumatol. 2017;69(8):1647–1660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28471497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng L, Zhao J, Deng Y, et al.
Human SLE variant NCF1-R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages. Ann Rheum Dis. 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34556485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen N, Fu Q, Deng Y, et al.
Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(36):15838–15843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2936646</ArticleId>
            <ArticleId IdType="pubmed">20733074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y, Zhao J, Sakurai D, et al.
MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS genetics. 2013;9(2):e1003336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3585142</ArticleId>
            <ArticleId IdType="pubmed">23468661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adrianto I, Wen F, Templeton A, et al.
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43(3):253–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103780</ArticleId>
            <ArticleId IdType="pubmed">21336280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y, Tsao BP. Updates in Lupus Genetics. Curr Rheumatol Rep. 2017;19(11):68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28983873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odhams CA, Roberts AL, Vester SK, et al.
Interferon inducible X-linked gene CXorf21 may contribute to sexual dimorphism in Systemic Lupus Erythematosus. Nat Commun. 2019;10(1):2164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6520347</ArticleId>
            <ArticleId IdType="pubmed">31092820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bentham J, Morris DL, Graham DSC, et al.
Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015;47(12):1457–1464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4668589</ArticleId>
            <ArticleId IdType="pubmed">26502338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heinz LX, Lee J, Kapoor U, et al.
TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7–9. Nature. 2020;581(7808):316–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7610944</ArticleId>
            <ArticleId IdType="pubmed">32433612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, Cai X, Wu J, et al.
Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015;347(6227):aaa2630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25636800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi T, Shimabukuro-Demoto S, Yoshida-Sugitani R, et al.
The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity. 2014;41(3):375–388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25238095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris VM, Harley ITW, Kurien BT, Koelsch KA, Scofield RH. Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing CXorf21. Front Immunol. 2019;10:578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6454867</ArticleId>
            <ArticleId IdType="pubmed">31001245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiang K, Largent AD, Arkatkar T, et al.
Cutting Edge: A Threshold of B Cell Costimulatory Signals Is Required for Spontaneous Germinal Center Formation in Autoimmunity. J Immunol. 2021;207(9):2217–2222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8530958</ArticleId>
            <ArticleId IdType="pubmed">34588220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson SW, Jacobs HM, Arkatkar T, et al.
B cell IFN-gamma receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. 2016;213(5):733–750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4854732</ArticleId>
            <ArticleId IdType="pubmed">27069113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giles JR, Kashgarian M, Koni PA, Shlomchik MJ. B Cell-Specific MHC Class II Deletion Reveals Multiple Nonredundant Roles for B Cell Antigen Presentation in Murine Lupus. J Immunol. 2015;195(6):2571–2579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4561209</ArticleId>
            <ArticleId IdType="pubmed">26268653</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
